Log in

Relevant bibliographies by topics / Structural valve deterioration / Journal articles

Journal articles on the topic 'Structural valve deterioration'

To see the other types of publications on this topic, follow the link: Structural valve deterioration.

Author: Grafiati

Published: 15 June 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Structural valve deterioration.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Foroutan, Farid, Gordon H. Guyatt, Catherine M. Otto, Reed A. Siemieniuk, Stefan Schandelmaier, Thomas Agoritsas, Per O. Vandvik, Sai Bhagra, and Rodrigo Bagur. "Structural valve deterioration after transcatheter aortic valve implantation." Heart 103, no. 23 (July 6, 2017): 1899–905. http://dx.doi.org/10.1136/heartjnl-2017-311329.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Atkins, B. Zane, and Gabriel S. Aldea. "“Drilling Down” on Structural Valve Deterioration." Journal of the American College of Cardiology 72, no. 5 (July 2018): 586. http://dx.doi.org/10.1016/j.jacc.2018.04.080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hernandez-Vaquero, Daniel, Rocio Diaz, Isaac Pascual, Jacobo Silva, and Cesar Moris. "Considerations When Evaluating Structural Valve Deterioration." Journal of the American College of Cardiology 72, no. 5 (July 2018): 586–87. http://dx.doi.org/10.1016/j.jacc.2018.04.081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Werner, Paul, Jasmin Gritsch, Sabine Scherzer, Christoph Gross, Marco Russo, Iuliana Coti, Alfred Kocher, Guenther Laufer, and Martin Andreas. "Structural valve deterioration after aortic valve replacement with the Trifecta valve." Interactive CardioVascular and Thoracic Surgery 32, no. 1 (November 22, 2020): 39–46. http://dx.doi.org/10.1093/icvts/ivaa236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Abstract OBJECTIVES Despite promising short- and mid-term results for durability of the Trifecta valve, contradictory reports of early structural valve deterioration (SVD) do exist. We investigated the incidence of SVD after surgical aortic valve replacement (SAVR) with the Trifecta in our single-centre experience. METHODS Data of 347 consecutive patients (mean age 71.6 ± 9.5 years, 63.4% male) undergoing SAVR with the Trifecta between 2011 and 2017 were analysed. Clinical and echocardiographic reports were obtained with a median follow-up of 41 months (1114 patient years). RESULTS Isolated SAVR was performed in 122 patients (35.2%), whereas 225 patients (64.8%) underwent concomitant procedures. The median EuroSCORE II was 4.0 (0.9; 7.1) and 30-day mortality was 3.7% (n = 13). Kaplan–Meier estimates for the freedom of overall mortality at 1, 5 and 7 years were 88.7 ± 1.7%, 73.7 ± 2.6% and 64.7 ± 4.2%, respectively. SVD was observed in 25 patients (7.2%) with a median time to first diagnosis of 73 months. Freedom of SVD was 92.5 ± 0.9% at 5 years and 65.5 ± 7.1% at 7 years. Thirteen patients underwent reintervention for SVD (6 re-SAVR, 7 valve-in-valve), resulting in a freedom of reintervention for the SVD of 98.5 ± 1.1% at 5 years and 76.9 ± 6.9% at 7 years. CONCLUSIONS We herein report one of the highest rates of SVD after SAVR with the Trifecta. These data indicate that the durability of the prosthesis decreases at intermediate to long-term follow-up, leading to considerable rates of reintervention due to SVD.

5

Kattach, Hassan, Clifford W. Barlow, and Sunil K. Ohri. "Structural valve deterioration of a pericardial bioprosthesis." JTCVS Open 9 (March 2022): 84–85. http://dx.doi.org/10.1016/j.xjon.2021.10.059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sénage, Thomas, Florence Gillaizeau, Thierry Le Tourneau, Basile Marie, Jean-Christian Roussel, and Yohann Foucher. "Structural valve deterioration of bioprosthetic aortic valves: An underestimated complication." Journal of Thoracic and Cardiovascular Surgery 157, no. 4 (April 2019): 1383–90. http://dx.doi.org/10.1016/j.jtcvs.2018.08.086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Issa, Issa Farah, Steen Hvitfeldt Poulsen, Farhad Waziri, Christian Torp Pedersen, Per Hostrup Nielsen, Lars Riber, Jordi S. Dahl, Peter Søgaard, Martin Agge Nørgaard, and Jacob Eifer Møller. "Structural valve deterioration in the Mitroflow biological heart valve prosthesis." European Journal of Cardio-Thoracic Surgery 53, no. 1 (September 28, 2017): 136–42. http://dx.doi.org/10.1093/ejcts/ezx321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Nardi, Paolo, Carlo Bassano, Antonio Pellegrino, and Giovanni Ruvolo. "Early structural valve deterioration of the Mitroflow biological valve prosthesis." European Journal of Cardio-Thoracic Surgery 54, no. 1 (March 29, 2018): 200–201. http://dx.doi.org/10.1093/ejcts/ezy136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Deutsch, Marcus-André, N. Patrick Mayr, Gerald Assmann, Albrecht Will, Markus Krane, Nicolo Piazza, Sabine Bleiziffer, and Ruediger Lange. "Structural Valve Deterioration 4 Years After Transcatheter Aortic Valve Replacement." Circulation 131, no. 7 (February 17, 2015): 682–85. http://dx.doi.org/10.1161/circulationaha.114.013995.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Tang, Gilbert H. L., Isaac George, and Vinayak N. Bapat. "Structural Valve Deterioration in Surgical Versus Transcatheter Aortic Valve Replacement." Journal of the American College of Cardiology 73, no. 21 (June 2019): 2785. http://dx.doi.org/10.1016/j.jacc.2019.02.073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Jamieson, WR Eric, Hilton Ling, Lawrence H. Burr, Guy J. Fradet, Robert T. Miyagishima, Samuel V. Lichtenstein, and A. Ian Munro. "Carpentier-Edwards Bioprosthesis: Structural Deterioration by Age Groups." Asian Cardiovascular and Thoracic Annals 5, no. 4 (December 1997): 193–98. http://dx.doi.org/10.1177/021849239700500402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

The Carpentier-Edwards supra-annular porcine bioprosthesis (second generation prosthesis) was implanted in 2438 patients in 2482 operations between 1982 and 1992. The mean age of the population was 64 years with a range from 21 years to 89 years. There were 1334 aortic and 934 mitral valve replacements. The population was divided into five groups: 21 to 40 years (n = 132); 41 to 50 years (n = 189); 51 to 60 years (n = 454); 61 to 70 years (n = 849); and over 70 years (n = 858). There was no difference in sunival by valve position for age groups 21 to 40 years and 41 to 50 years. Sunival within the age groups 51 to 60 years, 61 to 70 years, and over 70 years was greater for patients with aortic compared with mitral and multiple valve replacements. The freedom from structural valve deterioration at 10 years for all age groups was highest for valves in the aortic position. Patients with valves in the mitral position had a higher freedom from structural valve deterioration at 10 years than those who had multiple valve replacement, although not all the differences were significant. There was a lower incidence of structural valve deterioration in the older age groups. We concluded that the use of the Carpentier-Edwards supra-annular porcine bioprosthesis for aortic valve replacement can be extended to patients over 60 years of age, while its use for mitral valve replacement can be extended to those above 70 years of age.

12

Belhaj Soulami, Réda, Miguel Castro, Pascal Haigron, and Jean-Philippe Verhoye. "Structural valve deterioration does not alter tissue valves’ radiopaque landmarks: Implications for valve-in-valve therapy." Medical Hypotheses 127 (June 2019): 49–56. http://dx.doi.org/10.1016/j.mehy.2019.03.033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Sénage, Thomas, Thierry Le Tourneau, Yohann Foucher, Sabine Pattier, Caroline Cueff, Magali Michel, Jean-Michel Serfaty, et al. "Early Structural Valve Deterioration of Mitroflow Aortic Bioprosthesis." Circulation 130, no. 23 (December 2, 2014): 2012–20. http://dx.doi.org/10.1161/circulationaha.114.010400.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Olivito, Silvio, Stéphanie Lalande, Francesco Nappi, Nadjib Hammoudi, Cosimo D’Alessandro, Pierre Fouret, and Christophe Acar. "Structural deterioration of the cryopreserved mitral homograft valve." Journal of Thoracic and Cardiovascular Surgery 144, no. 2 (August 2012): 313–20. http://dx.doi.org/10.1016/j.jtcvs.2011.06.041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Eric Jamieson, W. R., D. Craig Miller, Cary W. Akins, A. Ian Munro, Donald D. Glower, Kathleen A. Moore, and Charmaine Henderson. "Pregnancy and bioprostheses: Influence on structural valve deterioration." Annals of Thoracic Surgery 60 (August 1995): S282—S287. http://dx.doi.org/10.1016/0003-4975(95)00308-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Baldeo, Candice, AbdulWahab Hritani, Cherisse Baldeo, and Robert Percy. "Does chemo-radiation predispose to structural valve deterioration?" International Journal of Cardiology 211 (May 2016): 53–54. http://dx.doi.org/10.1016/j.ijcard.2016.02.155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Della Barbera, Mila, Elena Pettenazzo, Ugolino Livi, Domenico Mangino, Gino Gerosa, Tomaso Bottio, Cristina Basso, Marialuisa Valente, and Gaetano Thiene. "Structural valve deterioration and mode of failure of stentless bioprosthetic valves." Cardiovascular Pathology 51 (March 2021): 107301. http://dx.doi.org/10.1016/j.carpath.2020.107301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Reul, Ross M., Mahesh K. Ramchandani, and Michael J. Reardon. "Transcatheter Aortic Valve-in-Valve Procedure in Patients with Bioprosthetic Structural Valve Deterioration." Methodist DeBakey Cardiovascular Journal 13, no. 3 (July 1, 2017): 132. http://dx.doi.org/10.14797/mdcj-13-3-132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Yamanaka, Shota, and Shuichiro Takanashi. "Early Structural Valve Deterioration of Tricuspid Pericardial Valve Caused by Native Valve Adhesion." Annals of Thoracic Surgery 109, no. 3 (March 2020): e175-e176. http://dx.doi.org/10.1016/j.athoracsur.2019.06.084.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Aoyagi, Shigeaki, Kei-ichiro Tayama, Teiji Okazaki, Yusuke Shintani, Michitaka Kono, Kumiko Wada, Ken-ichi Kosuga, Ryusuke Mori, and Hiroyuki Tanaka. "Structural Valve Deterioration in a Starr-Edwards Mitral Caged-Disk Valve Prosthesis." Circulation Journal 77, no. 1 (2013): 105–8. http://dx.doi.org/10.1253/circj.cj-12-0906.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Axtell, Andrea L., David C. Chang, Serguei Melnitchouk, Arminder S. Jassar, George Tolis, Mauricio A. Villavicencio, Thoralf M. Sundt, and David A. D'Alessandro. "Early structural valve deterioration and reoperation associated with the mitroflow aortic valve." Journal of Cardiac Surgery 33, no. 12 (December 2018): 778–86. http://dx.doi.org/10.1111/jocs.13953.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Cinelli, Michael, Leonard Schwartz, Jonathan Spagnola, Iosif Gulkarov, Frank Rosell, Adam Lackey, Mohammed Imam, and Charles Schwartz. "Early Structural Deterioration of a Sutureless Bioprosthetic Aortic Valve." Cardiology Research 11, no. 2 (2020): 113–17. http://dx.doi.org/10.14740/cr1013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Grunkemeier, Gary L., W. R. Eric Jamieson, D. Craig Miller, and Albert Starr. "Actuarial versus actual risk of porcine structural valve deterioration." Journal of Thoracic and Cardiovascular Surgery 108, no. 4 (October 1994): 709–18. http://dx.doi.org/10.1016/s0022-5223(94)70298-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Kaneko, Tsuyoshi, Igor Gosev, Marzia Leacche, and John G. Byrne. "Early Structural Valve Deterioration of the Mitroflow Aortic Bioprosthesis." Circulation 130, no. 23 (December 2, 2014): 1997–98. http://dx.doi.org/10.1161/circulationaha.114.013368.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Gennari, Marco, Gianluca Polvani, Mara Rubino, Francesco Arlati, Andrea Annoni, and Marco Agrifoglio. "Undiagnosed mitroflow bioprosthesis deformation causing early structural valve deterioration." General Thoracic and Cardiovascular Surgery 66, no. 9 (November 29, 2017): 543–45. http://dx.doi.org/10.1007/s11748-017-0868-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kang, Yoonjin, Ho Young Hwang, Suk Ho Sohn, Jae Woong Choi, Kyung Hwan Kim, and Ki‐Bong Kim. "Comparative analysis of structural valve deterioration after bioprosthetic tricuspid valve replacement: Bovine pericardial versus porcine valves." Artificial Organs 45, no. 8 (March 4, 2021): 911–18. http://dx.doi.org/10.1111/aor.13909.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Murashita, Takashi, David L. Joyce, Alberto Pochettino, John M. Stulak, and Lyle D. Joyce. "Concomitant Valve-In-Valve Transcatheter Aortic Valve Replacement and Left Ventricular Assist Device Implantation." Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 12, no. 2 (March 2017): 147–49. http://dx.doi.org/10.1097/imi.0000000000000360.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Redo aortic valve replacement (AVR) performed simultaneously with left ventricular assist device (LVAD) implantation carries potential for increased mortality rates. Although transcatheter AVR has been used for patients with previous LVAD placement, no literature reports concomitant valve-in-valve transcatheter AVR and LVAD implantation. Our patient had severe aortic prosthetic valve deterioration and advanced heart failure. Given the risks associated with reoperative aortic valve surgery, we chose transcatheter AVR at the time of LVAD implantation. Transthoracic echocardiography results showed severe aortic prosthetic valve deterioration with moderate aortic regurgitation as well as severe left ventricular dysfunction (ejection fraction, 11%). After redosternotomy, we performed transcatheter AVR via the ascending aorta and subsequent LVAD implantation. The postoperative course was uneventful. Generally, patients with structural deterioration of a bioprosthetic valve who report for LVAD therapy present considerable challenges to the surgeon. Concomitant transcatheter AVR offers a less-invasive alternative to surgical AVR that minimizes ischemic injury to myocardium.

28

Salaun, Erwan, Marie-Annick Clavel, Josep Rodés-Cabau, and Philippe Pibarot. "Bioprosthetic aortic valve durability in the era of transcatheter aortic valve implantation." Heart 104, no. 16 (May 7, 2018): 1323–32. http://dx.doi.org/10.1136/heartjnl-2017-311582.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

The main limitation of bioprosthetic valves is their limited durability, which exposes the patient to the risk of aortic valve reintervention. Transcatheter aortic valve implantation (TAVI) is considered a reasonable alternative to surgical aortic valve replacement (SAVR) in patients with intermediate or high surgical risk. TAVI is now rapidly expanding towards the lower risk populations. Although the results of midterm durability of the transcatheter bioprostheses are encouraging, their long-term durability remains largely unknown. The objective of this review article is to present the definition, mechanisms, incidence, outcome and management of structural valve deterioration of aortic bioprostheses with specific emphasis on TAVI. The structural valve deterioration can be categorised into three stages: stage 1: morphological abnormalities (fibrocalcific remodelling and tear) of bioprosthesis valve leaflets without hemodynamic valve deterioration; stage 2: morphological abnormalities and moderate hemodynamic deterioration (increase in gradient and/or new onset of transvalvular regurgitation); and stage 3: morphological abnormalities and severe hemodynamic deterioration. Several specifics inherent to the TAVI including valve oversizing, manipulation, delivery, positioning and deployment may cause injuries to the valve leaflets and increase leaflet mechanical stress, which may limit the long-term durability of transcatheter bioprostheses. The selection of the type of aortic valve replacement and bioprosthesis should thus take into account the ratio between the demonstrated durability of the bioprostheses versus the life expectancy of the patient. Pending the publication of robust data on long-term durability of transcatheter bioprostheses, it appears reasonable to select SAVR with a bioprosthesis model that has well-established long-term durability in patients with low surgical risk and long life expectancy.

29

Kiefer, Philipp, Joerg Seeburger, Michael W. A. Chu, Joerg Ender, Marcel Vollroth, Thilo Noack, Friedrich W. Mohr, and David M. Holzhey. "Reoperative Transapical Aortic Valve Implantation for Early Structural Valve Deterioration of a SAPIEN XT valve." Annals of Thoracic Surgery 95, no. 6 (June 2013): 2169–70. http://dx.doi.org/10.1016/j.athoracsur.2012.10.072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Takano, Tamaki, Tatsuichiro Seto, Shiho Asaka, Takamitsu Terasaki, Noburou Ohashi, Daisuke Fukui, and Jun Amano. "Structural Valve Deterioration of Porcine Bioprosthesis Soon after Mitral Valve Repair and Replacement." Annals of Thoracic and Cardiovascular Surgery 20, Supplement (2014): 717–19. http://dx.doi.org/10.5761/atcs.cr.13.02264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Nappi, Francesco, Cristiano Spadaccio, Massimo Chello, Mario Lusini, and Cristophe Acar. "Impact of Structural Valve Deterioration on Outcomes in the Cryopreserved Mitral Homograft Valve." Journal of Cardiac Surgery 29, no. 5 (July 14, 2014): 616–22. http://dx.doi.org/10.1111/jocs.12400.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Zakko, J., N. Matre, R. Tamer, M. Henn, A. Ganapathi, B. Whitson, N. Mokadam, and J. Bozinovski. "EARLIER STRUCTURAL VALVE DETERIORATION AND TIME TO REOPERATION IN AN EXTERNALLY WRAPPED VALVE." Canadian Journal of Cardiology 39, no. 10 (October 2023): S191. http://dx.doi.org/10.1016/j.cjca.2023.06.293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Zakko, J., N. Matre, R. Tamer, M. Henn, A. Ganapathi, B. Whitson, N. Mokadam, and J. Bozinovski. "EARLIER STRUCTURAL VALVE DETERIORATION AND TIME TO REOPERATION IN AN EXTERNALLY WRAPPED VALVE." Canadian Journal of Diabetes 47, no. 7 (November 2023): S157—S158. http://dx.doi.org/10.1016/j.jcjd.2023.10.296.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kuroda, Yuki, Akira Marui, Yoshio Arai, Atsushi Nagasawa, Shinichi Tsumaru, Ryoko Arakaki, Jun Iida, et al. "Impact of dialysis in patients undergoing bioprosthetic aortic valve replacement." Interactive CardioVascular and Thoracic Surgery 33, no. 3 (May 7, 2021): 348–53. http://dx.doi.org/10.1093/icvts/ivab106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Abstract OBJECTIVES To determine the incidence of bioprosthetic structural valve deterioration in dialysis patients undergoing aortic valve replacement compared to that in patients without dialysis. METHODS This single-centre retrospective observational study included 1159 patients who underwent aortic valve replacement using bioprosthetic valves for aortic stenosis and/or regurgitation at our institution between 2007 and 2017 [patients with dialysis (group D, n = 134, 12%) or without dialysis (group N, n = 1025, 88%)]. To adjust for potential differences between groups in terms of initial preoperative characteristics or selection bias, a propensity score analysis was conducted. The final sample that was used in the comparison included 258 patients, as follows: 129 patients with dialysis (group D) and 129 patients without dialysis (group N). The cumulative incidences of all-cause death, cardiac death and moderate or severe structural valve deterioration were estimated using the Kaplan–Meier method. RESULTS Operative mortality was significantly higher in group D than group N (9% vs 0%, P = 0.001). Kaplan–Meier analysis revealed that in group D, the incidence was significantly higher for all-cause death (P < 0.001, 50% vs 18% at 5 years), cardiac death (P = 0.001, 18% vs 5% at 5 years) and moderate or severe structural valve deterioration (P < 0.001, 29% vs 5% at 5 years) compared with group N. CONCLUSIONS The incidence of structural valve deterioration in dialysis patients undergoing aortic valve replacement was higher than that in patients without dialysis. Bioprosthetic valves should be carefully selected in dialysis patients undergoing aortic valve replacement.

35

Jamieson, W. R. Eric, and Alfred N. Gerein. "Mitroflow Pericardial Bioprosthesis: Experience to Seven Years." Asian Cardiovascular and Thoracic Annals 1, no. 3 (September 1993): 123–28. http://dx.doi.org/10.1177/021849239300100305.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Between 1983 and 1987, the Mitroflow pericardial prosthesis was implanted in 99 patients, ranging in age from 28 to 94 years (mean 62.8 years). Early mortality was 6.1% (6 patients), and late mortality was 4.8% per patient-year (22 patients). Total cumulative follow-up was 458 patient-years (mean 4.6 years). At 7 years, patient survival was 62% for aortic valve replacement and 63% for mitral valve replacement. The overall rate of valve-related complications was 7.4% per patient-year (34 events): thromboembolism, 2.8%; antithromboembolic-relatedhemorrhage, 1.1%; prosthetic valve endocarditis, 0.7%; non-structural dysfunction, 0.7%; and structural valve deterioration, 2.8%. At 7 years, freedom from thromboembolism was 80.3%, and freedom from prosthetic valve endocarditis was 95.5%. At 5 and 7 years, freedom from structural valve deterioration was 93.4% and 69.7%, respectively. At 5 years, freedom from structural valve deterioration was 97.3% for aortic valve replacement (AVR), 86.6% for mitral valve replacement (MVR), and 100% for multiple valve replacement (MR). At 7 years, freedom from structural valve replacement was 84.6% and 61.3% for AVR and MVR, respectively. At 7 years, overall freedom from reoperation was 68.2%; from valve-related mortality, 81.4%; from valve-related residual morbidity, 97.4%; and from treatment failure (valve-related mortality and residual morbidity), 79.0%. At 7 years, the Mitroflow pericardial bioprosthesis has provided satisfactory clinical performance, especially in the aortic position, with an acceptable freedom from structural valve deterioration.

36

Rheude, Tobias, Costanza Pellegrini, Salvatore Cassese, Jens Wiebe, Sophia Wagner, Teresa Trenkwalder, Hector Alvarez, et al. "Predictors of haemodynamic structural valve deterioration following transcatheter aortic valve implantation with latest-generation balloon-expandable valves." EuroIntervention 15, no. 14 (February 2020): 1233–39. http://dx.doi.org/10.4244/eij-d-19-00710.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Lobov, A., A. N. Kostyunin, T. V. Glushkova, D. K. Shishkova, B. R. Zainullina, E. A. Ovcharenko, A. N. Stasev, A. V. Evtushenko, and A. G. Kutikhin. "Proteomic profiling reveals unique signatures of structural bioprosthetic valve deterioration." Atherosclerosis 355 (August 2022): 41–42. http://dx.doi.org/10.1016/j.atherosclerosis.2022.06.349.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Hayatsu, Yukihiro, Takeshi Saito, Osamu Adachi, Kiichiro Kumagai, Masatoshi Akiyama, Naotaka Motoyoshi, Shunsuke Kawamoto, and Yoshikatsu Saiki. "Reoperation on a Starr–Edwards ball valve without structural deterioration." General Thoracic and Cardiovascular Surgery 60, no. 12 (May 29, 2012): 827–29. http://dx.doi.org/10.1007/s11748-012-0092-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Galiñanes, Manuel, Kelly Casós, Arnau Blasco-Lucas, Eduard Permanyer, Rafael Máñez, Thierry Le Tourneau, Jordi Barquinero, et al. "Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study." Biomolecules 12, no. 11 (October 31, 2022): 1606. http://dx.doi.org/10.3390/biom12111606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

The cause of structural valve deterioration (SVD) is unclear. Therefore, we investigated oxidative stress markers in sera from patients with bioprosthetic heart valves (BHVs) and their association with SVD. Blood samples were taken from SVD (Phase A) and BHV patients during the first 24 (Phase B1) and >48 months (Phase B2) after BHV implantation to assess total antioxidant capacity (TAC), malondialdehyde (MDA), and nitrotyrosine (NT). The results show that MDA levels increased significantly 1 month after surgery in all groups but were higher at 6 months only in incipient SVD patients. NT levels increased gradually for the first 24 months after implantation in the BHV group. Patients with transcatheter aortic valve implantation (TAVI) showed even higher levels of stress markers. After >48 months, MDA and NT continued to increase in BHV patients with a further elevation after 60–72 months; however, these levels were significantly lower in the incipient and established SVD groups. In conclusion, oxidative stress may play a significant role in SVD, increasing early after BHV implantation, especially in TAVI cases, and also after 48 months’ follow-up, but decreasing when SVD develops. Oxidative stress potentially represents a target of therapeutic intervention and a biomarker of BHV dysfunction.

40

Van Belle, Eric, Cédric Delhaye, and Flavien Vincent. "Structural Valve Deterioration at 5 Years of TAVR Versus SAVR." Journal of the American College of Cardiology 76, no. 16 (October 2020): 1844–47. http://dx.doi.org/10.1016/j.jacc.2020.09.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Li, Fei, Xu Wang, Yuetang Wang, Fei Xu, Xin Wang, Xuan Li, and Wei Wang. "Structural Valve Deterioration after Transcatheter Aortic Valve Implantation Using J-Valve: A Long-Term Follow-Up." Annals of Thoracic and Cardiovascular Surgery 26, no. 3 (2020): 158–65. http://dx.doi.org/10.5761/atcs.oa.19-00325.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Stankowski, Tomasz, Sleiman Sebastian Aboul-Hassan, Farzaneh Seifi-Zinab, Volker Herwig, Miroslava Kubikova, Axel Harnath, Dirk Fritzsche, and Bartłomiej Perek. "Severe structural deterioration of small aortic bioprostheses treated with valve-in-valve transcatheter aortic valve implantation." Journal of Cardiac Surgery 34, no. 1 (January 2019): 7–13. http://dx.doi.org/10.1111/jocs.13976.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Emir, Mustafa, Gürkan Uzunonat, Birol Yamak, A. Tulga Ulus, M. Kamil Göl, Zafer Iscan, S. Fehmi Katircioğlu, Binali Mavitaş, Oğuz Taşdemir, and Kemal Bayazit. "Effects of Pregnancy on Long-Term Follow-Up of Mitral Valve Bioprostheses." Asian Cardiovascular and Thoracic Annals 6, no. 3 (September 1998): 174–78. http://dx.doi.org/10.1177/021849239800600306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Between 1986 and 1990, 304 females between 11 and 45 (mean, 33.9 ± 6.9) years of age underwent isolated mitral valve replacement with a bioprosthesis. Thirty-nine of the 285 survivors experienced 48 pregnancies during the late follow-up period (group 1). Structural valve deterioration occurred in 25 (64.1%) of these patients and in 70 (28.4%) of the 246 patients (group 2) who did not become pregnant (p < 0.01). The mean time at which structural valve deterioration occurred was 7.01 ± 1.19 years postoperatively (range, 4.74 to 8.36 years) for group 1 patients and 6.76 ± 1.34 years (range, 2.33 to 10.17 years) for group 2 patients (p > 0.05). Freedom from structural valve deterioration at 10 years was 22.9% ± 8.11% for group 1 and 29.24% ± 6.09% for group 2 (p > 0.05). We concluded that pregnancy did not influence the long-term outcome after mitral valve replacement with a bioprosthesis.

44

Edelman, J. James, Jaffar M. Khan, Toby Rogers, Christian Shults, Lowell F. Satler, I. Itsik Ben-Dor, Ron Waksman, and Vinod H. Thourani. "Valve-in-Valve TAVR: State-of-the-Art Review." Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 14, no. 4 (July 22, 2019): 299–310. http://dx.doi.org/10.1177/1556984519858020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

An increasing number of surgically implanted bioprostheses will require re-intervention for structural valve deterioration. Valve-in-valve transcatheter aortic valve replacement (ViV TAVR) has become an alternative to reoperative surgery, currently approved for high-risk and inoperable patients. Challenges to the technique include higher rates of prosthesis–patient mismatch and coronary obstruction, compared to native valve TAVR. Herein, we review results of ViV TAVR and novel techniques to overcome the aforementioned challenges.

45

Wongkornrat, Wanchai, Kornkan Mahasawas, Punnarerk Thongcharoen, and Thaworn Subtaweesin. "Long Term Outcomes and Durability of Bioprosthetic Valve for Valve Replacement at Siriraj Hospital." Siriraj Medical Journal 74, no. 4 (April 1, 2022): 211–16. http://dx.doi.org/10.33192/smj.2022.26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Objective: Bioprosthesis has been used in cardiac valve replacement for a long time. However, structural valve deterioration is still a major cause of failure. There are several risk factors for valve deterioration. This study evaluates the risk factors of valve deterioration in the long term (10 years) at Siriraj Hospital.Materials and Methods: We retrospectively reviewed the medical records of 249 patients who underwent mitral or aortic valve replacement between January 2006 and December 2012 using various tissue valves, comprising Carpentier–Edwards porcine, Carpentier–Edwards Perimount bovine pericardial, Carpentier–Edwards Perimount Magna bovine pericardial, and St Jude Trifecta bovine pericardial types. The information from each patient was entered into a database at the time of the operation and followed up regularly, with a mean follow-up of 10 years.Results: After 10 years follow-up time, the incidence of valve deterioration events were 1.2% and 8.43% in the first five and ten years, respectively. The overall death rate during follow-up was 2.41%. There were three statistically significant risk factors (p < 0.05) of valve deterioration: gender (female) (p = 0.042), age ≤ 60 years old (p = 0.010) and St Jude Trifecta bovine pericardial valve (p = 0.004).Conclusion: In the surgical populations who underwent valve replacement at Siriraj Hospital with tissue valves, we found an acceptable long-term durability of the tissue valve. The risk factors of valve deterioration were female gender, age ≤ 60 years old, and St Jude Trifecta bovine pericardial valve.

46

Schamroth Pravda, Nili, Hana Vaknin Assa, Amos Levi, Guy Witberg, Yaron Shapira, Mordechai Vaturi, Katia Orvin, et al. "Tricuspid Structural Valve Deterioration Treated with a Transcatheter Valve-in-Valve Implantation: A Single-Center Prospective Registry." Journal of Clinical Medicine 11, no. 9 (May 9, 2022): 2667. http://dx.doi.org/10.3390/jcm11092667.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

The valve-in-valve (ViV) technique is an emerging alternative for the treatment of bioprosthetic structural valve deterioration (SVD) in the tricuspid position. We report on the outcomes of patients treated by a transcatheter tricuspid valve-in-valve (TT-ViV) implantation for symptomatic SVD in the tricuspid position during the years 2010–2019 at our center. Three main outcomes were examined during the follow-up period: TT-ViV hemodynamic data per echocardiography, mortality and NYHA functional class. Our cohort consisted of 12 patients with a mean age 65.4 ± 11.9 years, 83.3% male. The mean time from initial valve intervention to TT-ViV was 17.4 ± 8.7 years. The indications for TT-ViV were varied (41.7% for predominant regurgitation, 33.3% for predominant stenosis and 25.0% with a mixed pathology). All patients were treated with a balloon-expandable device. The mean follow-up was 3.4 ± 1.3 years. Tricuspid regurgitation was ≥ moderate in 57.2% of patients prior to the procedure and this decreased to 0% following the procedure. The mean transtricuspid valve gradients mildly decreased from the mean pre-procedural values of 9.0 mmHg to 7.0 mmHg at one month following the procedure (p = 0.36). Mortality at one year was 8.0% (95% CI 0–23). At the baseline, 4 patients (33.3%) were in NYHA functional class III/IV; this was reduced to 2 patients (18.2%) at the one year follow-up and both were in NYHA III. The TT-ViV procedure offered a safe, feasible and less invasive treatment option for patients with SVD in our detailed cohort.

47

Watanabe, Tatsuya, Noriyuki Tokunaga, Keita Maruno, Hideo Yoshida, and Masahiko Kuinose. "Redo aortic valve replacement due to early structural valve deterioration in a trifecta valve: A case report." International Journal of Surgery Case Reports 86 (September 2021): 106381. http://dx.doi.org/10.1016/j.ijscr.2021.106381.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Angelillis, Marco. "A valve-in-valve transcatheter aortic valve implantation with commissural alignment using advanced imaging reconstruction: a case report." Clinical Cardiology and Cardiovascular Interventions 3, no. 10 (October 16, 2020): 01–05. http://dx.doi.org/10.31579/2641-0419/090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Abstract:

Transcatheter valve in valve (ViV) implantation actually represents a valid alternative to surgical reinterventions in patients with previous surgical aortic valve replacement (AVR). In patients less than 80 years old, it is crucial to correctly position the new valve leaving a feasible and easy access to coronary ostia, both for future percutaneous coronary intervention (PCI) than for a future possible TAVinTAV procedure. We report a 71 year old man with prior AVR presented with structural valve deterioration (SVD) leading to severe aortic stenosis. In order to guarantee comfortable coronary access we aligned, the commissures of the new percutaneous valve with the ones of the surgical bioprothesis by reconstructing the headframes of the surgical bioprosthesis with computer tomography (CT) and fluoro-CT.

49

Kotani, Mitsuhisa, Masaaki Toyama, Masanori Katoh, Yuji Kato, Kazuhiro Hisamoto, and Yukiharu Sugimura. "Early Structural Valve Deterioration of Third-Generation Porcine Bioprosthesis in Patients." Japanese Journal of Cardiovascular Surgery 39, no. 6 (2010): 339–42. http://dx.doi.org/10.4326/jjcvs.39.339.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Koizumi, Shintaroh, Kaoru Matsuura, Yoshio Kobayashi, and Goro Matsumiya. "Low-gradient structural valve deterioration in a patient of cardiac sarcoidosis." Journal of Cardiovascular Echography 27, no. 2 (2017): 59. http://dx.doi.org/10.4103/jcecho.jcecho_47_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles